Arno Therapeutics Announces Issuance of First Onapristone

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arno Therapeutics Announces Issuance of First Onapristone Patent

FLEMINGTON, N.J., June 4, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that United States Patent Number 9,046,534 has been issued by the U.S. Patent and Trademark Office (USPTO) related to the methods and systems for identifying and treating patients with anti-progestin sensitive tumors using the Company's lead product candidate, onapristone. The patent, which Arno has exclusively licensed from Invivis Pharmaceuticals, Inc., establishes that the focal nuclear distribution pattern of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.

Alex Zukiwski, MD, Chief Executive Officer of Arno Therapeutics, commented, "As we continue advancing the clinical development of our lead compound, onapristone, we are committed to protecting our investment through a robust and defensible intellectual property portfolio. This method patent strengthens our IP around the identification of patients most likely to benefit from treatment with our unique anti-progestin hormone blocker."

Onapristone is an oral, anti-progestin hormone blocker that has been shown in previous Phase II clinical trials (not sponsored by Arno) to exhibit considerable anti-tumor activity in patients with breast cancer. In pre-clinical testing, onapristone has been shown to block the activation of PR, which is believed to be a mechanism that inhibits the growth of APR driven breast, endometrial and other gynecological tumors. APR has the potential to function as a biomarker of anti-progestin activity, as detected by a companion diagnostic currently under development with Arno's partner, Leica Biosystems.

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. Arno has exclusive worldwide rights to develop and market three innovative product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors, as well as infectious diseases. For more information about the company, please visit www.arnothera.com .

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the Company's belief in the protection to be afforded the Company from the patents described herein, the timing, progress and anticipated results of the clinical development of onapristone, including the ability to identify and treat those patients most likely to benefit from onapristone, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. Arno may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made here. Various important factors could cause actual results or events to differ materially from these forward-looking statements. Such factors include, among others, risks that the results of clinical trials will not support claims or beliefs concerning the effectiveness of onapristone or any other product candidates, the ability to successfully develop a diagnostic to identify APR tumors, the ability to finance the development of Arno's product candidates, regulatory risks, and reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2014. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

The Ruth Group Lee Roth (investors) (646) 536-7012 Kirsten Thomas (media) (646) 536-7014 Arno Therapeutics Lawrence Kenyon (862) 703-7171

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 86

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 72

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 7

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 123

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 108

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 99

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 143

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
DSFederal Takes On USDA NIFA Grants System Support Work

Updated Category News Views 0

A Quiet Contract With Real Operational Weight Grant paperwork rarely gets anybody’s pulse racing, yet a busted grants system can gum up research money from coast to coast in a hurry. DSFederal has won work supporting the U.S. Department of Agriculture’s National Institute of Food and Agriculture, or NIFA, through its Grants Management and Reporting System, known as...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 112

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Nike Locks In Chicago Marathon Partnership Through 2036 Deal

Updated Category News Views 13

Twenty-eight miles of pavement, training plans, and branded shoes are not a quarterly earnings release, but Nike just made a very long-term statement in Chicago. The company and the Bank of America Chicago Marathon have extended their partnership through 2036, preserving a relationship that began in 2008. For a brand rebuilding credibility with runners, that kind of...

Continue Reading

Top 5 Most Recently Viewed Articles

Bret Baier's Exclusive Interview with Trump on FOX Super Bowl Show

Updated Category News Views 296

Bret Baier's Exclusive Interview with President Donald Trump In a highly anticipated television event, Bret Baier, the chief political anchor for FOX News Channel (FNC), will engage in a significant one-on-one interview with President Donald Trump during the FOX Super Bowl LIX pregame show. This exclusive interview will air in the 3 PM/ET hour and is set to be a revealing...

Continue Reading
3D Systems Corporation Lawsuit Notification: What Investors Should Know

Updated Category News Views 169

3D Systems Corporation Lawsuit Overview The Gross Law Firm has issued a notice regarding an important class action lawsuit that involves shareholders of 3D Systems Corporation (NASDAQ: DDD). This legal action arises from allegations concerning misleading statements made by the company during a specific class period that could affect investors significantly. Understanding...

Continue Reading
5W PR Takes Charge of Marketing Strategies for Bedsure Pet

Updated Category News Views 191

5W PR Appointed as Agency of Record for Bedsure Pet Bedsure Pet, a leader in pet essentials, has recently welcomed 5W PR as their Agency of Record. This collaboration aims to elevate the brand's visibility and credibility in the competitive pet products market. About Bedsure Pet Products Bedsure Pet is celebrated for offering a wide range of high-quality pet products,...

Continue Reading
Itafos Enhances Financial Stability by Selling St George Shares

Updated Category News Views 155

Itafos Strengthens Financial Position Through Share Monetization HOUSTON, Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) has made headlines with its recent strategic move to partially monetize its equity interest in St George Mining Limited. This transaction, framed within the context of a larger corporate strategy, was initially announced following the sale of the Araxá...

Continue Reading
Hawkeye Invest AS Expands Stake in PCI Biotech Holding ASA

Updated Category News Views 343

Hawkeye Invest AS Enhances its Investment in PCI Biotech Holding ASA In a significant move, Hawkeye Invest AS, under the leadership of Øystein Barmen, has increased its stake in PCI Biotech Holding ASA by acquiring an additional 240,000 shares. This latest purchase has elevated their total ownership to 2,000,000 shares, representing a noteworthy 5.36% of the total shares...

Continue Reading